Lifestyle change trial targets waistline and kidneys in high-risk patients
NCT ID NCT06715735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a specially designed health behavior program can help people with metabolic syndrome and chronic kidney disease reduce their waist size and improve kidney function. Researchers will compare the program to usual care in 160 adults, measuring changes in waist circumference, kidney function, diet, and physical activity. The goal is to see if a lifestyle-focused approach can better manage these two linked conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants are 18 years old and above; * Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol/L or treatment for hypertriglycerides, HDL-C\<1.03 mmol/L in men or \<1.29 mmol/L in women or treatment for low HDL-C, FG ≥5.6 mmol/L or previously diagnosed type 2 diabetes, and BP ≥ 130/85 mmHg or treatment for hypertension), and CKD; * Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven; * Own a smartphone for accessing WeChat; * Being able to communicate in Chinese. Exclusion Criteria: * Participants who have medical contraindications to exercise, including walking; * Participants who have already started dialysis or kidney transplant; * Current participation in another clinical trial related to health behaviour change or medical trial; * Participants who have doctor-diagnosed psychiatric illness; * Adjustment of medication within half a year; * Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a weekly weight drug quiet gout attacks?
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Does better dialysis keep parathyroid hormone in check?
- Biobank aims to unlock the mysteries of calciphylaxis